The abstract is read at the publisher; the summary is JClub's.
In 22 patients with anterior nucleus of the thalamus (ANT) deep brain stimulation for drug-refractory epilepsy, responders show distinct ANT spectral trajectories over 4 years, including higher β1/θ ratios.
- Why it matters: Long-term DBS effects vary and are hard to predict because benefits emerge gradually and reliable physiological biomarkers are lacking to track response.
- What they did: The study analyzed longitudinal intracranial recordings from ANT over 4 years, comparing spectral trajectories between clinical responders and non-responders and testing whether frequency ratios could discriminate outcomes early.
- The result: Dynamic ANT spectral biomarkers, especially high- to low-frequency ratios such as β1/θ, enabled early discrimination of clinical outcomes and supported the feasibility of adaptive stimulation guided by these signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.